ES2392551T3 - Composiciones que comprenden quitosano adecuadas para el tratamiento terapéutico global o la prevención global de síndrome metabólico - Google Patents

Composiciones que comprenden quitosano adecuadas para el tratamiento terapéutico global o la prevención global de síndrome metabólico Download PDF

Info

Publication number
ES2392551T3
ES2392551T3 ES07726617T ES07726617T ES2392551T3 ES 2392551 T3 ES2392551 T3 ES 2392551T3 ES 07726617 T ES07726617 T ES 07726617T ES 07726617 T ES07726617 T ES 07726617T ES 2392551 T3 ES2392551 T3 ES 2392551T3
Authority
ES
Spain
Prior art keywords
chitosan
composition according
global
metabolic syndrome
ascorbic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07726617T
Other languages
English (en)
Spanish (es)
Inventor
Umberto Cornelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
COR CON INTERNATIONAL Srl
Original Assignee
COR CON INTERNATIONAL Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by COR CON INTERNATIONAL Srl filed Critical COR CON INTERNATIONAL Srl
Application granted granted Critical
Publication of ES2392551T3 publication Critical patent/ES2392551T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
ES07726617T 2006-03-03 2007-03-02 Composiciones que comprenden quitosano adecuadas para el tratamiento terapéutico global o la prevención global de síndrome metabólico Active ES2392551T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI20060384 2006-03-03
IT000384A ITMI20060384A1 (it) 2006-03-03 2006-03-03 Composizioni comprendenti chitosano atte al trattamento terapeutico complessivo o alla prevenzione complessiva della sindrome metabolica
PCT/EP2007/052023 WO2007099170A1 (en) 2006-03-03 2007-03-02 Compositions comprising chitosan suitable for comprehensive therapeutic treatment or comprehensive prevention of the metabolic syndrome

Publications (1)

Publication Number Publication Date
ES2392551T3 true ES2392551T3 (es) 2012-12-11

Family

ID=38019452

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07726617T Active ES2392551T3 (es) 2006-03-03 2007-03-02 Composiciones que comprenden quitosano adecuadas para el tratamiento terapéutico global o la prevención global de síndrome metabólico

Country Status (8)

Country Link
US (1) US9050356B2 (https=)
EP (1) EP1996207B1 (https=)
JP (1) JP5557451B2 (https=)
ES (1) ES2392551T3 (https=)
IT (1) ITMI20060384A1 (https=)
MX (1) MX2008011289A (https=)
PL (1) PL1996207T3 (https=)
WO (1) WO2007099170A1 (https=)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54148090A (en) 1978-05-11 1979-11-19 Ajinomoto Co Inc Peroral cholesterol-depressant
US4223023A (en) 1978-10-12 1980-09-16 Ivan Furda Nonabsorbable lipid binder
JP2614297B2 (ja) * 1988-12-27 1997-05-28 三栄源エフ・エフ・アイ株式会社 ソーマチンの凝集・分離防止及び甘味改善法
JPH04108734A (ja) 1990-08-29 1992-04-09 Kurita Water Ind Ltd 降コレステロール剤
JP2667351B2 (ja) * 1992-03-24 1997-10-27 麒麟麦酒株式会社 食餌脂質消化吸収阻害剤および飲食品
JP2507907B2 (ja) 1992-06-08 1996-06-19 水産庁長官 血圧降下用の食品添加物質および抗高血圧剤
US5550019A (en) * 1993-05-26 1996-08-27 La Jolla Cancer Research Foundation Methods of identifying compounds which alter apoptosis
US6180148B1 (en) 1996-05-28 2001-01-30 Asama Chemical Co., Ltd. Method for cooking fresh noodles in a microwave oven
US20030069206A1 (en) 1998-07-10 2003-04-10 Nichols Everett J. Methods and kits for absorbing fat
PT1105123E (pt) 1998-08-14 2004-08-31 Hoffmann La Roche Composicoes farmaceuticas contendo inibidores da lipase e quitosano
JP3371843B2 (ja) 1999-02-25 2003-01-27 扶桑化学工業株式会社 ロングライフ麺およびその製造方法
US20020016307A1 (en) * 1999-10-27 2002-02-07 Mullins John Jason Gentry Pharmaceutical composition with both a lipase inhibitor and a lipophilic polysaccharide and an improved method for treating adiposity
DE10054450A1 (de) 2000-09-06 2002-03-28 Guillermo Pasch Alonso Verfahren zur Modifikation von Getreidemahlerzeugnissen, nach dem Verfahren hergestellte Produkte und deren Verwendung
JP5024807B2 (ja) 2001-03-21 2012-09-12 独立行政法人水産総合研究センター 血圧上昇の抑制組成物
JP2003113089A (ja) * 2001-10-04 2003-04-18 Gotoo Corporation:Kk 脂質蓄積性阻害およびコレステロール低下作用を有するキトサン含有製剤および飲食品
JP2003238602A (ja) 2002-02-20 2003-08-27 Marino Forum 21 血糖値上昇抑制性物質
ITRM20030127A1 (it) 2003-03-24 2004-09-25 Osvaldo Legnini Composizione alimentare, pasta alimentare funzionale
KR100520007B1 (ko) * 2003-05-19 2005-10-11 건 식 조 혈압 강하 기능을 가지는 키토산 함유 소금의 제조방법
NZ549535A (en) 2004-03-17 2010-11-26 Novartis Ag Use of aliskiren for treating renal and other disorders
CN1692782A (zh) 2005-06-26 2005-11-09 苟春虎 降压好酸奶片
RU2290185C1 (ru) 2005-07-26 2006-12-27 Дмитрий Николаевич Мясников Композиция для нормализации липидного обмена и снижения массы тела и способ её получения

Also Published As

Publication number Publication date
WO2007099170A1 (en) 2007-09-07
EP1996207A1 (en) 2008-12-03
US9050356B2 (en) 2015-06-09
PL1996207T3 (pl) 2013-01-31
JP2009531306A (ja) 2009-09-03
JP5557451B2 (ja) 2014-07-23
ITMI20060384A1 (it) 2007-09-04
EP1996207B1 (en) 2012-08-08
MX2008011289A (es) 2009-01-27
US20090258839A1 (en) 2009-10-15

Similar Documents

Publication Publication Date Title
Marcus et al. Sex-specific determinants of increased left ventricular mass in the Tecumseh Blood Pressure Study.
KR20120059207A (ko) 동충하초 추출물 또는 이로부터 분리된 코디세핀을 유효성분으로 하는 불면증 개선 및 치료용 약학 조성물
US20200188327A1 (en) Formulations for extending lifespan and healthspan
CN101239069A (zh) 可提供活性甲基或参与甲基转移的化合物的应用
JP2018502079A (ja) ユウリコマ・ロンギフォリア抽出物並びに免疫系の増強及び／又は刺激におけるその使用
Rangineni et al. Diuretic, hypotensive, and hypocholesterolemic effects of Eclipta alba in mild hypertensive subjects: a pilot study
McIntyre et al. Prevalence of hypertension, obesity and smoking in three Indian communities in northwestern Ontario
US7645795B2 (en) Method for treating amyotrophic lateral sclerosis
ES2392551T3 (es) Composiciones que comprenden quitosano adecuadas para el tratamiento terapéutico global o la prevención global de síndrome metabólico
US20200100535A1 (en) Dietary supplement for lowering blood sugar, increasing immunity, and increasing cardiac function and increasing physical stamina
Xiao et al. The efficacy of cerebrolysin in patients with vascular dementia: Results of a Chinese multicentre, randomised, double-blind, placebo-controlled trial
Chen et al. Evaluation of gabapentin enacarbil on cardiac repolarization: a randomized, double-blind, placebo-and active-controlled, crossover thorough QT/QTc study in healthy adults
Tran et al. Shamanic Kambô frog hyponatremic toxicity leading to brain death: a case report
JP4779316B2 (ja) ジコッピ配合モノアミン再取り込み阻害剤
CN105919096B (zh) 一种保健食品组合物及其制剂和用途
JP6565085B2 (ja) 低血糖症状緩和剤
CN101803732A (zh) 一种具有辅助降血脂功能的保健食品及其制备方法
MORGULIS et al. Hippuric acid synthesis as a test of renal function
Ferreira et al. Dysphagic Complaint Evaluation on Patients on Otorrinolaryngology Ambulatory at Onofre Lopes University Hospital
Subramanian et al. Cysticercosis of the oral cavity: an often misdiagnosed entity
Panigrahi et al. Routine Body Checkup & Good Health Tips for Elder Person
Siriwardena Specific health issues in ethnic minority groups
CN105770087A (zh) 一种治疗糖尿病、高脂血症、原发性高血粘度的蒙药组合物
RU2634248C2 (ru) Ректальные суппозитории антидиабетического действия
GRANIRER The urinary excretion of creatine in arthritis